APLS Valuation

Apellis Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

27.940

+0.19(0.685%)1D

Overview
Forecast
Valuation
Earnings

APLS Relative Valuation

APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.

Historical Valuation

Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.54 is considered Undervalued compared with the five-year average of -21.23. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 31.12 to 43.53 according to relative valuation methord. Compared to the current price of 27.94 USD , Apellis Pharmaceuticals Inc is Undervalued By 10.22%.

Relative Value

Fair Zone

31.12-43.53

Current Price：27.94

10.22%

Undervalued

-138.33

Trailing

Forward

-56.25

EV/EBITDA

Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBITDA of -56.25. The 5-year average EV/EBITDA is -20.76. The thresholds are as follows: Strongly Undervalued below -271.71, Undervalued between -271.71 and -146.23, Fairly Valued between 104.72 and -146.23, Overvalued between 104.72 and 230.20, and Strongly Overvalued above 230.20. The current Forward EV/EBITDA of -56.25 falls within the Historic Trend Line -Fairly Valued range.

-516.94

EV/EBIT

Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBIT of -516.94. The 5-year average EV/EBIT is -31.31. The thresholds are as follows: Strongly Undervalued below -150.04, Undervalued between -150.04 and -90.67, Fairly Valued between 28.05 and -90.67, Overvalued between 28.05 and 87.41, and Strongly Overvalued above 87.41. The current Forward EV/EBIT of -516.94 falls within the Strongly Undervalued range.

3.54

Apellis Pharmaceuticals Inc. (APLS) has a current PS of 3.54. The 5-year average PS is 37.68. The thresholds are as follows: Strongly Undervalued below -68.67, Undervalued between -68.67 and -15.50, Fairly Valued between 90.86 and -15.50, Overvalued between 90.86 and 144.04, and Strongly Overvalued above 144.04. The current Forward PS of 3.54 falls within the Historic Trend Line -Fairly Valued range.

69.46

P/OCF

Apellis Pharmaceuticals Inc. (APLS) has a current P/OCF of 69.46. The 5-year average P/OCF is -59.59. The thresholds are as follows: Strongly Undervalued below -347.72, Undervalued between -347.72 and -203.66, Fairly Valued between 84.48 and -203.66, Overvalued between 84.48 and 228.55, and Strongly Overvalued above 228.55. The current Forward P/OCF of 69.46 falls within the Historic Trend Line -Fairly Valued range.

286.56

P/FCF

Apellis Pharmaceuticals Inc. (APLS) has a current P/FCF of 286.56. The 5-year average P/FCF is -16.74. The thresholds are as follows: Strongly Undervalued below -127.71, Undervalued between -127.71 and -72.23, Fairly Valued between 38.75 and -72.23, Overvalued between 38.75 and 94.24, and Strongly Overvalued above 94.24. The current Forward P/FCF of 286.56 falls within the Strongly Overvalued range.

Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 22.40. Compared to its 3-year average P/B ratio of 21.62 , the current P/B ratio is approximately 3.64% higher. Relative to its 5-year average P/B ratio of 16.92, the current P/B ratio is about 32.42% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 0.13%. Compared to its 3-year average FCF yield of -7.64%, the current FCF yield is approximately -101.66% lower. Relative to its 5-year average FCF yield of -8.22% , the current FCF yield is about -101.54% lower.

22.40

P/B

Median3y

21.62

Median5y

16.92

0.13

FCF Yield

Median3y

-7.64

Median5y

-8.22

Competitors Valuation Multiple

The average P/S ratio for APLS's competitors is 7.08, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 3.54, which is -50.04% above the industry average. Given its robust revenue growth of -10.61%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

APLS.O

Apellis Pharmaceuticals Inc

MoonLake Immunotherapeutics

Loss

3.49B

PTGX.O

Protagonist Therapeutics Inc

Mirum Pharmaceuticals Inc

Performance Decomposition

Market capitalization of APLS decreased by 28.66% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -18.86 to -23.61.

The secondary factor is the Revenue Growth, contributed -10.61%to the performance.

Overall, the performance of APLS in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-10.61%

199.69M → 178.49M

Revenue Growth

25.19%

-18.86 → -23.61

Margin Expansion

-43.24%

-26.80 → -15.21

P/E Change

-28.66%